Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
Cancer Medicine · 2024
DOI: 10.1002/cam4.70238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hyundong Yoon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Lysosomes. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
Lysosomal dysfunction (LD) impacts cytokine regulation, inflammation, and immune responses, influencing the development and progression of cancer. Inflammation is implicated in the pathogenesis of myeloproliferative neoplasm (MPN). With a hypothesis that LD significantly contributes to MPN carcinogenesis by inducing abnormal inflammation, our objective was to elucidate the pathophysiological mechanisms of MPN arising from an LD background.
Methods
Genotyping of the LD background was performed in a cohort of MPN patients (n = 190) and healthy controls (n = 461). Logistic regression modeling, utilizing genotype data, was employed to estimate the correlation between LD and MPN. Whole transcriptome sequencing (WTS) (LD carriers = 8, non‐carriers = 6) and single‐cell RNA sequencing data (LD carriers = 2, non‐carriers = 2, healthy controls = 2) were generated and analyzed.
Results
A higher variant frequency of LD was observed in MPN compared to healthy controls (healthy, 4.9%; MPN, 7.8%), with the highest frequency seen in polycythemia vera (PV) (odds ratio = 2.33, p = 0.03). WTS revealed that LD carriers exhibited upregulated inflammatory cytokine ligand–receptor genes, pathways, and network modules in MPNs compared to non‐carriers. At the single‐cell level, there was monocyte expansion and elevation of cytokine ligand–receptor interactions, inflammatory transcription factors, and network modules centered on monocytes. Notably, Oncostatin‐M (OSM) consistently emerged as a candidate molecule involved in the pathogenesis of LD‐related PV.
Conclusions
In summary, an LD background is prevalent in MPN patients and leads to increased cytokine dysregulation and inflammation. OSM, as one of the potential molecules, plays a crucial role in PV pathogenesis by impairing lysosomal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Bioinformatics Institute, Seoul National University, Seoul, Republic of Korea.
- BK21 FOUR Intelligence Computing, Seoul National University, Seoul, Republic of Korea.
- Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea.
- Interdisciplinary Program in Artificial Intelligence, Seoul National University, Seoul, Republic of Korea.
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Bonil Koo, Youngil Koh, Sung-Soo Yoon
Förderung
- Sanofi
Zitieren
APA
Yoon, H., Lee, D., Song, S., Koo, B., Park, J., Kim, T. K., Kim, S., Kim, S., Hong, J., Byun, J. M., Shin, D. Y., Kim, I., Koh, Y., & Yoon, S. S. (2024). Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm. Cancer Medicine. https://doi.org/10.1002/cam4.70238
Vancouver
Yoon H, Lee D, Song S, Koo B, Park J, Kim TK, et al. Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm. Cancer Medicine. 2024. doi:10.1002/cam4.70238
BibTeX
@article{Yoon2024,
author = {Yoon, Hyundong and Lee, Dohoon and Song, Seulki and Koo, Bonil and Park, Jihyun and Kim, Tae Kon and Kim, Sun and Kim, Sheehyun and Hong, Junshik and Byun, Ja Min and Shin, Dong-Yeop and Kim, Inho and Koh, Youngil and Yoon, Sung-Soo},
title = {Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70238}
}
EUVIMED